Stop Guessing with Medication

The infrastructure that makes medication work in the real world

June 2026

Disclaimer & Forward-Looking Statements

NOT FOR DISSEMINATION TO THE GENERAL PUBLIC

ABOUT THIS PRESENTATION

This investor presentation (this "**Presentation**") is dated as of April 16th, 2026 based on information available at the time and is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the "**Transaction**") involving Queue Ventures Ltd. ("**Queue**") and Custom Health, Inc. (together with its direct and indirect subsidiaries, collectively, the "**Company**" or "**Custom Health**"), Custom FundCo Inc., Custom Merger Sub, Inc. and Queue BC SubCo Inc. (together, the "**Parties**" and each a "**Party**"). The information contained herein does not purport to be all-inclusive or necessarily contain all the information that a prospective investor may desire in investigating a prospective investment in a Party, and none of the Parties, or any of their respective representatives or affiliates makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation (and any other information, whether written or oral, that has been or will be provided to you). The information contained herein is preliminary and is subject to update, completion, revision, verification and amendment without notice, and such changes may be material. The attached material is provided to you on the understanding that as a sophisticated investor, you will understand and accept its inherent limitations, will not rely on it in making any investment decision, and will use it only for purpose of discussing with your advisors your preliminary interest in investing in a Party. No statement contained herein should be considered binding on any party. Accordingly, none of the Parties nor any of their respective shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortuous, statutory or otherwise, in respect of the accuracy or completeness of the information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising from the use of this Presentation. None of the Parties undertakes or agrees to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. This Presentation does not constitute an offer to sell or a solicitation to buy securities. The Presentation is not and under no circumstances is it to be construed as a prospectus or a public offering. Neither the delivery of this Presentation, at any time, nor any sales made pursuant hereto, will imply that the information contained herein is correct as of any time subsequent to the date of this Presentation.

The Company currently operates in a highly competitive and highly regulated market landscape. There can be no guarantee that the Company will achieve any of its intended targets.

Custom Health is not a "reporting issuer", as such term is defined under applicable Canadian securities laws, in any province or territory of Canada and is not listed on any stock exchange. Potential Canadian investors are advised that Custom Health is not required to file a prospectus or similar document with any securities regulatory authority in Canada qualifying the resale of any securities to the public in any province or territory of Canada. There is currently no market for any securities of Custom Health and a market for such securities is not expected to develop. Each potential investor must be prepared to bear the economic risk of investing in the securities for an indefinite period. Potential investors are not to construe the contents of this Presentation as legal, tax, accounting or investment advice.

FORWARD-LOOKING STATEMENTS

This Presentation includes "forward-looking statements" and "forward-looking information" (together, "**forward-looking statements**") within the meaning of applicable securities laws. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target", or negatives of these terms or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, the Transaction, the terms, timing and completion of the Transaction, statements regarding the growth and development of the Company's or the entity resulting from the Transaction's (the "**Resulting Issuer**") business, statements regarding the Company's or the Resulting Issuer's strategies, development and growth plans and objectives, the ability of the Company and the Resulting Issuer to complete further acquisitions of pharmacies or other strategic businesses and assets and realize upon cost-savings or business synergies as a result of such acquisitions, estimates and forecasts of other financial and performance metrics including for the 2025 and 2026 fiscal years, and projections of market opportunity and market share.

Forward-looking statements are based on certain material assumptions and analysis made by the Company, and the opinions and estimates of management as of the date such statements are made and they represent management's best judgment based on facts and assumptions that management considers reasonable in light of its experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, including, among others, assumptions with respect to: the completion of the Transaction including the timing and terms for same, commercialization, growth plans, objectives, cash flows, the completion of target acquisitions and the terms thereof, the demand for the Company's products and services, future demand and trends in industries in which the Company may participate, the Company's ability to achieve expected synergies cost savings and revenue, the Company's ability to access financing on favorable terms from time to time, the continuation of executive and operating management or the non-disruptive replacement of them on competitive terms, the regulatory environments in which the Company operates, and stable market and general economic conditions. However, these assumptions are inherently imprecise. The Company makes no representation that reasonable businesspeople in possession of the same information would reach the same conclusions. Although the Company believes that the assumptions underlying forward-looking statements are reasonable, they may prove to be incorrect and the Company cannot assure that actual results will be consistent with such statements. Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements or the information contained in such statements.

Whether actual results, performance or achievements will conform to the Company's expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including, without limitation: risks associated with the timing, cost and terms of the Transaction; the ability of the Parties to obtain all requisite approvals including of the Toronto Stock Exchange (the "**TSX**") and shareholders in respect of the Transaction; costs associated with the Transaction or to consummate the Transaction at all; that the Transaction may divert management attention away from business operations and corresponding disruptions to growth and acquisition plans; litigation risks; regulatory risks associated with a listing in Canada for an entity whose operations exist primarily in the United States; currency and exchange rate fluctuations; the ability of the Resulting Issuer to meet the initial listing requirements of the TSX; the Company's potential requirement for additional funding to develop its business and its ability to acquire such funding on commercially acceptable terms; and risks relating to the following: liabilities associated with acquired companies or assets; failure to achieve expected synergies, cost savings, sales, revenue, and other financial performance metrics; changes to the regulatory environments in which the Company operates and/or may operate; litigation or regulatory action; the ability of the Company to obtain appropriate insurance and financing on commercially reasonable terms; the ability of the Company to maintain all licenses and permits necessary for the Company to carry out its businesses; the Company's inability to maintain or improve its competitive position; future demand and trends in sales failing to meet the Company's expectations for the operations of the Company; the Company's failure to retain key personnel and hire additional personnel needed to develop its business; the Company's failure to adequately evaluate its current business and future prospects; and changes to applicable laws of any jurisdiction in which the Company operates or proposes to operate.

These risks, uncertainties, assumptions and other factors could cause the Company's actual results, performances, achievements and experience to differ materially from the Company's expectations, future results, performances or achievements expressed or implied by the forward-looking statements. The forward-looking statements contained herein are presented for the purpose of assisting readers in understanding the Company's expected financial and operating performance and the Company's plans and objectives, and may not be appropriate for other purposes. You should read this information with the understanding that the Company's actual future results may be materially different from what it expects. These forward-looking statements are expressly qualified in their entirety by this cautionary statement. The Company disclaims any obligation to update forward-looking statements, except as required by law.

CONFIDENTIALITY

This Presentation and the information contained herein (and any other information, whether written or oral, that has been or will be provided to you) constitutes confidential information, is provided to you on the condition that you agree that you will hold it in strict confidence and not reproduce, disclose, forward or distribute it in whole or in part without the prior written consent of the Company and is intended for the recipient hereof only. Without limiting the generality of the foregoing, by accepting this Presentation, the recipient will have be deemed to have agreed (i) to maintain the confidentiality of this document and the information contained herein, (ii) to protect such information in the same manner the recipient would protect its own confidential information, which shall be at least a reasonable standard of care, (iii) not to reproduce this Presentation in whole or in part and (ii) to promptly destroy of return all copies of this Presentation and any analyses, compilations, studies or other documents prepared by or on behalf of the recipient and containing or reflecting any information in this Presentation upon the Company's written request. Any failure to comply with these restrictions may constitute a violation of applicable law.

Disclaimer & Forward-Looking Statements

NON-GAAP FINANCIAL MEASURES

In this Presentation, the Company has used the terms Annual Recurring Revenue (ARR), Rx-Reoccurring Revenue (RRR), EBITDA and CAGR (the "Non-GAAP Financial Measures"), which are financial measures that are not defined by International Financial Reporting Standards ("IFRS") but are used by management to evaluate the performance of the Company and its business. The Non-GAAP Financial Measures may also be used by investors, financial institutions and credit rating agencies to assess the Company's performance and ability to service debt. The intent of the Non-GAAP Financial Measures is to provide additional useful information to investors and analysts; however, the measures do not have any standardized meaning under IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. The measure should not, therefore, be considered in isolation or used in substitute for measures of performance prepared in accordance with IFRS. Other issuers may calculate the Non-GAAP Financial Measures substantially differently.

The Company defines ARR and RRR which are used interchangeably by the Company as the amount of revenue that may be derived or expected to be derived on an annual basis per patient or set of patients, as may be applicable and includes all sources of such revenue including, without limitation, from government agencies or insurers. The Company defines EBITDA as earnings before interest, tax, depreciation and amortization excluding items such as other non-operating income or expenses, financial income or expenses, hedging operations, exploration expenses, impairment of assets and foreign currency exchange differences. The Company defines CAGR as the compounded annual grow rate of a value over a given period of time. The Non-GAAP Financial Measures should not be construed as alternatives for figures determined in accordance with IFRS. The Company believes ARR and RRR are meaningful indicators of the Company's operational turnover and growth, and provides a measure of consistency over time and is an indicator management uses internally to measure the Company's performance. The Company believes that EBITDA is a meaningful indicator of the Company's operating profit, shown as a percentage of its revenue, and provides a measure of consistency over time and is an indicator management uses internally to measure the Company's performance. The Company believes that CAGR is a meaningful indicator of the Company's growth in revenue and operations over time and provides a measure of measure of overall consistency and is an indicator management uses internally to measure the Company's performance.

FINANCIAL INFORMATION

The financial information and data contained in this Presentation has been prepared by management to the Company and has not been reviewed or audited by any independent accounting or auditing firm. Certain monetary amounts, percentages and other figures included in this Presentation have been subject to rounding adjustments. Certain other amounts that appear in this Presentation may not sum due to rounding.

USE OF PROJECTIONS

This Presentation contains financial forecasts with respect to the Company's projected financial or operational results, including Revenue, Gross Profits, EBITDA and Number of Patients for the Company and its segments for fiscal years 2025 and 2026. The Company's independent auditors have not audited, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, they did not express an opinion or provide any other form of assurance with respect thereto for the purpose of this Presentation. These projections should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Accordingly, there can be no assurance that the prospective results are indicative of the future performance of the Company or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved.

UNITED STATES CAUTIONARY LANGUAGE

This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. Any such offer to sell or solicitation of an offer to buy the securities described herein or during the presentation will be made only pursuant to subscription documentation. Any such offering will be made in the United States in reliance upon an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), for an offer and sale of securities that does not involve a public offering, and the offer and sale of the securities will be conditioned on the receipt of representations, warranties and agreements of prospective purchasers to establish that exemption.

Any securities described in this Presentation have not been, and will not be, registered under the U.S. Securities Act and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the securities may not be resold, pledged, hypothecated or otherwise disposed of or transferred except in accordance with the registration requirements of the U.S. Securities Act and any applicable state securities laws or pursuant to an applicable exemption from such registration requirements of the U.S. Securities Act and any applicable state securities laws.

THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS COMMUNICATION. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

TRADEMARKS

Queue and the Company have proprietary rights to trademarks, service marks and trade names used in this Presentation that are important to their business, many of which are registered under applicable intellectual property laws. This Presentation also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this presentation may appear without the ®, ™or SM symbols, but such references are not intended to indicate, in any way, that Queue, the Company or any third party, as applicable, will not assert, to the fullest extent permitted under applicable law, its rights or the right of the applicable licensor to these trademarks, trade names and service marks. Queue and the Company do not intend their use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, any other parties.

INDUSTRY AND MARKET DATA

In this Presentation, the Company relies on and refer to certain information and statistics obtained from third-party sources, which it believes to be reliable. The Company has not independently verified the accuracy or completeness of any such third-party information. You are cautioned not to give undue weight to such industry and market data.

STATUTORY RIGHTS OF ACTION

This Presentation may be considered an offering memorandum thereby granting the potential purchasers statutory rights and contractual rights of action. Securities legislation in certain provinces and territories of Canada may provide a purchaser with remedies for rescission or damages if an offering memorandum (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal advisor. For a brief summary, please see "Statutory Rights of Action" on page 34 of this Presentation.

Custom Health Inc. – Corporate Overview

- The infrastructure that makes medication work in the real world — connecting pharmacy, in-home technology, and pharmacist-led clinicians
- Proprietary platform (AdhereNet®, spencer, PatchCap) creates continuous visibility into therapy
- Proven impact: 98% medication adherence, 42% reduction in unnecessary drugs, 27% lower opioid utilization
- Scalable growth model: organic expansion + disciplined M&A (4 acquisitions in 16 months)
- Experienced leadership across healthcare, technology and capital markets

Company Snapshot

Head Office:	Kelowna, BC
Founded:	2021
Employees/Contractors:	250+
Run rate Revenue:	USD $48M(1)
Pharmacies:	8
Patient Outreach:	2.2M Annually(2)

Annualized Run Rate Revenue as of September 30, 2025

(1) Includes revenue from completed pharmacy acquisitions in Ohio and Indiana (InnovativeRx). Annualized run rate revenue based on the nine months ended September 30, 2025, as per the information circular filed on Sedarplus
(2) Company data 2024.

The Problem

Medication therapy breaks down in practice[1]

Patients struggle to stay on track

75%

of people in the U.S. struggling to follow their medication schedules[2]

Poorly managed medication drives avoidable costs


CNN Health Sign In

US spends most on health care but has worst health outcomes among high-income countries, new report finds

By Jacqueline Howard, CNN
5 minute read · Published 12:01 AM EST, Tue January 31, 2023

Providers lack visibility between visits

Medication data alone isn't enough; it must be understood and acted on in the context of care.

(1) Fragmented care and chronic illness patient outcomes: A systematic review (2023).
(2) Medication Adherence: Helping Patients Take Their Medicines As Directed, Jan-Feb 2012, National Library of Medicine.

The Solution: Medication Therapy Infrastructure Platform

We operate the system that turns real-world data into action.

Pharmacy infrastructure deploys

Pharmacy + in-home technology control therapy and establish the flow of continuous, real-world data

Clinical infrastructure acts

Pharmacist-led clinicians interpret, engage and intervene to improve outcomes

Real-world performance at scale

$48M — **Annualized Revenue run-rate[(1)]**
Proforma including two acquisitions

2.2M — **Annual Patient Outreaches[(2)]**
Proactive touchpoints to identify issues and support earlier intervention

98% — **Medication Adherence[(3)]**
Achieved through continuous monitoring and pharmacist-led engagement

From deployment → to visibility → to intervention → to measurable performance

(1) Includes revenue from completed pharmacy acquisitions in Ohio and Indiana (InnovativeRx). Annualized run rate revenue based on the nine months ended September 30, 2025, as per the information circular filed on Sedarplus
(2) Company data 2024.
(3) BMC Geriatrics, "Medication adherence support of an in-home electronic medication dispensing system for individuals living with chronic conditions: a pilot randomized controlled trial".

Custom Health AI: Supporting Data-Driven Clinical Decision-Making

Our platform supports continuous learning by analyzing real-world medication and patient data to inform clinical workflows, improve care coordination, and support better patient outcomes.



(1) Number of daily health insights based on Company data as of date of this presentation. The Company serves approximately 15K patients in LTC facilities with oneMAR® and 3,750 patients at home with Spencer. Each patient generates 3-4 daily data insights equaling 75,000 daily insights

Extending Care into the Home for Continuous Medication Management

We deploy technology into the home to manage medication routines, continuously monitor, and engage patients between visits.

- Pharmacist-personalized medication organization
- Automated reminders, prompts, and dispensing
- Continuous monitoring and real-time connectivity
- Proactive outreach from pharmacist-led clinicians
- Integration with connected in-home devices

Real-World Performance

91%
PATIENT RESPONSE RATE[1]

7.6M
MONITORED DOSES IN 2024 [2]

42%
REDUCTION IN UNNECESSARY DRUGS [3]

27%
REDUCTION IN OPIOID UTILIZATION [4]

(1) Company data based on 146,774 survey questions asked to U.S. patients.
(2) 3.04 million pouches dispensed in 2024 = 3.04 million monitored pouches x 2.5 drugs/pouch = 7.6 million monitored doses in 2024.
(3) Polypharmacy program with WEA Trust ~4,000 participants.
(4) Nationwide Humana opioid program (n=8,675). Custom Health study (Oct 26, 2021–Oct 25, 2022; avg. age 64) showed a 27% reduction in average daily morphine equivalent dose over 12 months. Results reflect the opinion of the overseeing physician.

Custom Health Footprint



(1) Potential future States/Provinces reflects regions where the company is seeking additional acquisition opportunities. There is no guarantee that an acquisition will be completed in these regions.

Custom Health Business Model

Two Patient Channels (Funnels):

1. Health Plans, Medicare, Medicaid

Fee for Service →

← Cost Savings

2. Physician Groups

Fee for Service →

← New Revenue

Double-Stacked Revenue Model[(1)]

(Annual Revenue per Patient)

1	Pharmacy Revenue	$4,000-6,900[(2)]
2	Tech - Enabled Clinical Revenue	$960-1,800[(3)]

~$5,000-8,700

Combined Annual Revenue per Patient

driven by continuous monitoring, intervention, and coordinated medication management

(1) Revenue reflective of primary drug patients and government and insurance companies. Company data. The combination of pharmacy services and clinical services provide for higher profit margins on a per patient basis.

(2) Reflects Rx revenue for Canadian ($337/month or $4,044/year) and U.S. ($575/month or$6,900/year) patients, respectively. This measure for U.S. law purposes is a non-IFRS measure which would require reconciliation under Regulation G of the Securities Act of 1933.

(3) Tech-Enabled Clinical revenue per patient is dependent on geography and channel; economics exclude technology licensing and clinical consulting revenue. Reflects tech-enabled revenue for Canadian ($80/month or $960/year) and U.S. ($150/month or $1,800/year) patients, respectively. Includes device rental + (RTM/RPM/BHI/CCM)

Financial Projections





2026E and 2027E do not include additional acquisitions other than IRX (Indiana and Ohio)
Proforma financials based on preliminary unaudited financials for Q1-2026 for both Custom Health and IRX

Delivering Measurable Value for Providers and Health Plans

We improve patient outcomes while aligning financial incentives across providers and health plans—enabling more efficient, coordinated care.

$1.8K/patient

Annual incremental revenue for a provider(1)

$32K/member

Annual estimated savings for a health plan (2)

Trusted by leading Providers and health plans

Commonwealth Pain & Spine — Treating You to A Better Life.

Humana

Elevance Health

Georgia Medicaid

Blue Cross Blue Shield of Michigan

TennCare

Outcomes

BKC Pain Specialists & Regenerative Medicine Clinic

Missouri Department of Mental Health

(1) Illustrative calculation based on 12 months × ~$150 / patient / month in incremental revenue, derived from billing for 16+ vitals and two 20-minute clinical care interactions, using 2024 National Average Reimbursement rates (March–December). Annualized illustrative incremental revenue of approximately $1,800 per patient.

(2) Average savings per member ($702k / 22 patients = $31.9k / patient). Core Services Of East Tennessee – Enabling Technology Section – 2021 trend analysis savings.

Competitive Advantage

A unified system vs. fragmented point solutions

Digital Pharmacy	Medical Devices	Virtual Care	Data & AI Analytics
CAPSULE	pillo	Teladoc HEALTH	HealthCatalyst
EXACTCARE PHARMACY	livi	hims & hers	HEALWELL AI
fuzehealth	HERO	omada	TEMPUS
alto			

custom health

Most solutions address a single part of medication therapy — prescribing, dispensing, or monitoring. Custom Health is the platform infrastructure that connects pharmacy, in-home technology, and pharmacist-led clinicians into a unified system that enables continuous visibility and early action in care.

Defined M&A Playbook for Growth

Disciplined add-on acquisition strategy powered by Custom Health's integrated model.

Defined M&A Playbook

1. Target network and independent pharmacies—including single-site operators and small regional chains—in priority payor-covered markets, including technology-enabled partners, to reduce integration risk and accelerate growth.
2. Execute acquisitions at market-based valuations, aligned to revenue, EBITDA, and integration potential.
3. Drive post-acquisition value through continuous monitoring, pharmacist-led intervention, and expanded patient access via payer networks.
4. Scale across broader payor populations while improving efficiency through operating leverage.

Completed four pharmacy acquisitions in 16 months[(1)], demonstrating a repeatable acquisition and integration model

A Pipeline for Future Growth

Pipeline of 70+ pharmacies representing 200,000+ patients[(2)]

Significant long-term acquisition opportunity across the U.S. and Canada[(2)]

Success Scaling Acquired Pharmacy Revenue[(3)]



(1) Saskatoon Jun 2021, Chilliwack & Langley Aug 2021, Nashville Sept 2022.
(2) 2023 NCPA Digest: State of the industry, Cardinal Health; statistics provided in the box represent the potential acquisition pool. (200k patients x $575/patient x 12 months = $1.38 billion).
(3) Company data, Custom Pharmacy Toronto Q2 2021 – Q3 2022.

Why Custom Health Wins

Custom Health is the infrastructure that makes medication therapy work.

1. **Mission-Critical, Scalable Solution**
   Technology-enabled model improving medication adherence[1], care coordination, and care delivery efficiency.

2. **Large and Expanding Market Opportunity**
   68M U.S. adults manage multiple chronic conditions[2], representing a **$528B** non-adherence problem[3] and a growing, policy-backed market.

3. **Defensible Integrated Platform**
   Proprietary system connecting pharmacy, in-home technology, and clinicians to create continuous visibility and meaningful barriers to entry.

4. **Proven Growth Engine**
   Disciplined execution has delivered **90%** revenue growth in 18 months[4], with a scalable acquisition pipeline.

5. **Recurring, Scalable Revenue Model**
   Integrated pharmacy and clinical services reinforce each other, increasing revenue per patient.

(1) Medication adherence support of an in-home electronic medication dispensing system for individuals living with chronic conditions: a pilot randomized controlled trial, January 14, 2021, BMC Geriatrics; (2) Prevalence of Multiple Chronic Conditions Among U.S. Adults, 2018, September 17, 2022, CDC (3) Cost of Prescription Drug–Related Morbidity and Mortality, March 26, 2018, Sage Journals; Cost-related nonadherence to prescription medications in the U.S.: a scoping review, Sep 6, 2018, National Library of Medicine (4) Company data, Custom Pharmacy Toronto Q2 2021 – Q3 2022 (5) New Data Reveal a Stable Independent Pharmacy Market, August 1, 2022, PCMA.

Capital Structure

PRO FORMA FULLY DILUTED CAPITALIZATION

Security / Holder Group	Millions
Basic Shares Outstanding (Post Offering)	23.29
Convertible Notes	1.92
Warrants	1.27
Options/RSU	2.36
Fully Diluted Shares (Post Offering)	**28.84**

Pro Forma Ownership Mix



:

Experienced, Operator-Led Leadership Team

Shane Bishop, Founder & CEO

Pharmacist, entrepreneur, and patent holder with 20+ years in healthcare innovation. Founded and scaled multiple ventures, including Catalyst Healthcare (acquired by Custom Health) and Paragon Pharmacies (publicly traded prior to acquisition by Shoppers Drug Mart). Now leads Custom Health's transformation of care delivery through tech-enabled, pharmacist-led services.

Rahul Chopra, Founder & Chairman

Serial entrepreneur and technology leader with 20+ years building scalable platforms across infrastructure, IT, and commercialization. Deep expertise in public-private partnerships, capital strategy, and transformative business models. Previously raised $200M+ and led $1B+ in transactions. Holds foundational patents in visual voicemail and unified messaging.

Jason Nalewany, Chief Financial Officer

Chartered Professional Accountant (CPA-CA) with 20+ years in public company finance and capital markets. Former CFO of publicly listed issuers (CSE: MTLC; TSXV: LEXI). Brings expertise in financings, M&A, IFRS reporting, and public company compliance. Began career at PricewaterhouseCoopers and brings the governance required to support Custom Health as a publicly traded issuer.

Led by proven operators with 30+ years in pharmacy, healthcare and technology.

IBM
McKESSON
intel
QHR Technologies
Meta
Medical Pharmacies
Outcomes
Shoppers Drug Mart
Radisys
Guardian Pharmacy Services
Canadian Pharmacists Association
Catalyst

custom health

Thank you.

info@customhealth.com

Comparable Companies

2026-06-08		Price	Market Cap	Enterprise Value	Revenue Consensus		EV/Sales	
					C2026E	C2027E	C2026E	C2027E
Company Name	**Ticker**							
Addus Homecare Corporation	NASDAQ: ADUS	128.24	2344.7	2394.4	2117.7	2218.6	1.1x	1.1x
Alcidion Group Limited	ASX:ALC	0.11	145.4	132.5	50.9	53.3	2.6x	2.5x
Health Catalyst, Inc.	NASDAQ:HCAT	2.69	198.6	284.6	366.9	339.7	0.8x	0.8x
Kneat.com Inc.	TSX:KSI	5.42	521.5	496.8	78.2	96.5	6.4x	5.1x
Tempus AI, Inc.	NasdaqGS:TEM	64.65	11608.9	12555.0	2222.4	2715.0	5.6x	4.6x
Veeva Systems Inc.	NYSE:VEEV	240.35	39042.5	29003.7	4301.4	5086.3	6.7x	5.7x
VitalHub Corp.	TSX:VHI	7.17	453.6	334.9	130.8	142.0	2.6x	2.4x
WELL Health Technologies Corp.	TSX:WELL	4.84	1236.2	2074.2	1580.4	1688.1	1.3x	1.2x
Healwell AI Inc.	TSX:AIDX	0.87	263.3	328.1	125.0	135.0	2.6x	2.4x
Mean							*3.7x*	*3.2x*

Source: CapIQ

Risk Factors

General Risks

Downturns or volatility in general economic conditions could have a material adverse effect on the Company's business, financial condition, results of operations and liquidity.

Industry consolidation may result in increased competition, which could result in a reduction in revenue.

The Company depends on growth in the end markets that use its products. Any slowdown in the growth of these end markets could adversely affect its financial results.

The Company is dependent on a limited number of distributors and end customers. The loss of, or a significant disruption in the relationships with any of these distributors or end customers, could significantly reduce the Company's revenue and adversely impact the Company's operating result.

If the Company fails to accurately anticipate and respond to rapid technological change in the industries in which the Company operates, the Company's ability to attract and retain customers could be impaired and its competitive position could be harmed.

The Company's competitive position could be adversely affected if it is unable to meet customers' or device manufacturers' quality requirements.

If the Company is unable to expand or further diversify its customer base, its business, financial condition, and results of operations could suffer.

If the Company's products and services do not conform to, or are not compatible with, existing or emerging industry standards, demand for its products may decrease, which in turn would harm the Company's business and operating results.

The Company is subject to risks and uncertainties associated with international operations, which may harm its business.

The Company's company culture has contributed to its success and if the Company cannot maintain this culture as it grows, its business could be harmed.

Loss of key management or other highly skilled personnel, or an inability to attract such management and other personnel, could adversely affect the Company's business.

The Company may not be able to effectively manage its growth and may need to incur significant expenditures to address the additional operational and control requirements of its growth, either of which could harm the Company's business and operating results.

Shifts in the Company's product mix or customer mix may result in declines in gross margin.

The Company may pursue mergers, acquisitions, investments and joint ventures, which could divert its management's attention or otherwise disrupt its operations and adversely affect its results of operations.

The Company may not manage its growth effectively.

The Company may need additional capital to pursue our business objectives and respond to business opportunities, challenges or unforeseen circumstances, and we cannot be sure that additional financing will be available.

Our forecasts and projections are based on assumptions, analyses and internal estimates developed by our management. If these assumptions, analyses or estimates prove to be incorrect or inaccurate, our actual operating results may differ materially from those forecasted or projected.

The market adoption of our product is evolving and may develop more slowly or differently than we expect. Our future success depends on the growth and expansion of these markets and our ability to adapt and respond effectively to evolving markets.

We rely on trade secrets, designs, experiences, work flows, data processes, software and know-how.

We are subject to cybersecurity risks to operational systems, security systems, infrastructure, integrated software in our products and customer data processed by us or third-party vendors or suppliers and any material failure, weakness, interruption, cyber event, incident or breach of security could hinder the effective operation of our business.

Both Queue and the Company will incur significant transaction costs in connection the proposed acquisitions of the pharmacies in Ohio and Indiana.

The Company may not successfully or timely consummate the proposed acquisition of the pharmacies in Ohio and Indiana, and the closing of such transactions are subject to a variety of risks, including, without limitation, the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed acquisitions or that the approval of the stockholders of the pharmacy entities is not obtained.

The consummation of the proposed pharmacy acquisitions is subject to a number of conditions and if those conditions are not satisfied or waived, the definitive agreement may be terminated in accordance with its terms and the acquisitions may not be completed.

Stock and Capitalization Risks

The Company has a history of losses and may incur significant expenses and continuing losses for the foreseeable future.

The market price of the Resulting Issuer's common shares may be highly volatile.

The Company's operating results may have significant period-to-period fluctuations, which would make it difficult to predict our future performance.

Raising additional funds by issuing securities may cause dilution to existing shareholders or restrict the Resulting Issuer's operations.

The Resulting Issuer does not intend to pay cash dividends. Consequently, any gains from an investment in its securities will likely depend on whether the price of the common share increases.

The Resulting Issuer's executive officers and directors will own a significant percentage of the common shares and could exert significant influence over matters requiring shareholder approval, including takeover attempts.

Failure to meet the maintenance criteria of the stock exchange may result in the delisting of the Resulting Issuer's common shares, which could result in lower trading volumes, liquidity and prices of the common shares and make it more difficult for the Resulting Issuer to raise capital.

If industry or financial analysts do not publish research or reports about the Resulting Issuer's business, or if they issue inaccurate or unfavorable research regarding the common shares, the share price and trading volume could decline.